Glatopa

Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Carcinoma in Situ + 1 more
Treatment
1 FDA approval
20 Active Studies for Glatopa

What is Glatopa

GlatiramerThe Generic name of this drug
Treatment SummaryGlatiramer acetate is a medication made of four natural amino acids: glutamic acid, alanine, tyrosine, and lysine. It is an immunomodulator used to reduce the frequency of relapses in people with relapsing-remitting multiple sclerosis. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons.
Copaxoneis the brand name
Glatopa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Copaxone
Glatiramer
2002
9

Approved as Treatment by the FDA

Glatiramer, otherwise known as Copaxone, is approved by the FDA for 1 uses such as Multiple Sclerosis .
Multiple Sclerosis
Helps manage Multiple Sclerosis

Effectiveness

How Glatopa Affects PatientsGlatiramer acetate is a mix of four amino acids (L-glutamic acid, L-alanine, L-tyrosine, and L-lysine) used to treat relapsing multiple sclerosis. It works by helping to modify the immune system processes that cause MS. Patients taking glatiramer acetate have been shown to have fewer relapses than those taking a placebo or IFNb-1a. However, some patients experience side effects after taking the drug, including chest pain, injection site side effects, and hepatic injury. There is also a chance that glatiramer acetate
How Glatopa works in the bodyGlatiramer acetate works to treat multiple sclerosis by changing how the body's immune system reacts. It binds to certain molecules on cells that are involved in MS and prevents them from causing inflammation. It also encourages the body to make anti-inflammatory cells that can cross the blood-brain barrier and produce helpful cytokines. These cells help suppress MS and can even induce production of T-regulatory cells that further suppress the disease.

When to interrupt dosage

The recommended dosage of Glatopa is contingent upon the indicated condition. The quantity of dosage fluctuates in accordance with the technique of delivery (e.g. Solution - Subcutaneous or Injection, solution - Subcutaneous) featured in the table beneath.
Condition
Dosage
Administration
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Carcinoma in Situ
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Relapsing Remitting Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous

Warnings

Glatopa has two demarcated contraindications, so it should not be utilized when suffering from any of the ailments specified in the following table.Glatopa Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
There are 20 known major drug interactions with Glatopa.
Common Glatopa Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Antilymphocyte immunoglobulin (horse).
Apremilast
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Apremilast.
Glatopa Toxicity & Overdose RiskIn mice and rats given 15 times the normal dose of glatiramer acetate, there were no reports of increased cancer risk. Tests in the lab did not find any mutagenic effects. Animals given the drug did not have any reproductive or developmental issues. If someone takes too much glatiramer acetate, they may experience severe side effects such as liver damage, loss of fat, or dead skin at the injection site. Treatment for an overdose should focus on managing the symptoms and providing supportive care.

Glatopa Novel Uses: Which Conditions Have a Clinical Trial Featuring Glatopa?

193 active trials are being carried out to determine the efficacy of Glatopa in treating Multiple Sclerosis.
Condition
Clinical Trials
Trial Phases
Multiple Sclerosis
120 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Carcinoma in Situ
3 Actively Recruiting
Not Applicable, Phase 4
Multiple Sclerosis
0 Actively Recruiting
Relapsing Remitting Multiple Sclerosis
14 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 4, Early Phase 1

Glatopa Reviews: What are patients saying about Glatopa?

2.3Patient Review
4/29/2016
Glatopa for Relapsing Form of Multiple Sclerosis
I am joining the ranks of those who have had issues after switching from Copaxone to Glatopa. I was fine for five years while on Copaxone, but soon after being switched over in January, I developed uvitis and now I'm experiencing a flare-up that isn't responding well to prednisone.
2Patient Review
10/1/2015
Glatopa for Relapsing Form of Multiple Sclerosis
About three months ago, my insurance company switched me to the generic form of this medication. Recently, I've been feeling even more tired and have started forgetting things like appointments and conversations. I'm going to see a doctor soon to discuss this further.
1.3Patient Review
2/23/2019
Glatopa for Relapsing Form of Multiple Sclerosis
I was on copaxone for about 7 years. No increases in legions during that time. My insurance forced me to switch to generic. After 1 year on generic, legions more than doubled on brain and quadrupled on spine. Doctor immediately switched me to Gilenya. 1 year later, no advancement in legions or worsening of pain and fatigue. Thought it was just my time to get worse until looking into it again and seeing like issues; however, upon further research I discovered that this is a common occurrence with this medication changeover.
1.3Patient Review
4/20/2019
Glatopa for Relapsing Form of Multiple Sclerosis
Cigna forced me to switch from Copaxone to Glatopa, and soon after I started having severe symptoms. Numbness, tingling in my extremities, difficulty using my hands, clumsiness in one foot, and difficulty thinking are just some of the problems I experienced. This drug was a big mistake.
1Patient Review
12/12/2015
Glatopa for Relapsing Form of Multiple Sclerosis
I was moved to this generic Glatopa after 12 years on Copaxone. I had a few attacks, some minor numbness and fatigue before, but since switching to Glatopa I've had two major attacks within 3 months. The first one caused me to lose my hearing in my left ear, and now I'm having trouble with my legs - they're weak and unsteady. I'm not happy with Glatopa at all.
View All Reviews

Patient Q&A Section about glatopa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Glatopa treat?

"The FDA has approved Glatopa for the treatment of MS in adults."

Answered by AI

What type of drug is Glatopa?

"The usage of Glatopa is to treat patients with relapsing forms of multiple sclerosis, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS. Glatopa is the generic version of Copaxone."

Answered by AI

Is Glatopa the same as Copaxone?

"The primary difference between Glatopa and Copaxone is that Glatopa is a generic version of the latter. In other words, the active ingredient, clinical benefits, and method of administration are all identical between the two medication options; however, Glatopa is typically more affordable than Copaxone."

Answered by AI

How long does it take for Glatopa to work?

"The effects of Copaxone may not be noticeable for several months after starting injections, with most people reporting it takes six to nine months to notice an effect. In some people it may take longer for the effects to be noticeable."

Answered by AI

Clinical Trials for Glatopa

Have you considered Glatopa clinical trials? We made a collection of clinical trials featuring Glatopa, we think they might fit your search criteria.
Have you considered Glatopa clinical trials? We made a collection of clinical trials featuring Glatopa, we think they might fit your search criteria.
Have you considered Glatopa clinical trials? We made a collection of clinical trials featuring Glatopa, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top